Navigation Links
Misonix Schedules Fourth Quarter and Fiscal Year 2009 Financial Results Conference Call; October 1, 2009 at 4:30 p.m. Eastern
Date:9/29/2009

FARMINGDALE, N.Y., Sept. 29 /PRNewswire-FirstCall/ -- Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, today announced plans to release fourth quarter and fiscal year ended June 30, 2009 financial results on Thursday afternoon, October 1, 2009. Michael A. McManus, President and Chief Executive Officer and Richard Zaremba, Senior VP and Chief Financial Officer, will host a conference call at 4:30 p.m. Eastern on Thursday,October 1, 2009 to discuss the Company's fourth quarter and fiscal 2009 financial results.

Shareholders and other interested parties may participate in the conference call by dialing (866) 515-2909 (domestic) or (617) 399-5123 (international) and entering access code 61977194, a few minutes before the start of the call. A simultaneous webcast will be available via Misonix's website at www.misonix.com. The call will be archived on the Company's website for at least 90 days.

A recording of the live-call will be available approximately 2 hours after the event through October 8, 2009. The dial-in number to listen to the recording is (888) 286 8010 or (617) 801 6888. The replay access code is 35358896.

About Misonix:

Misonix, Inc. (Nasdaq: MSON) designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

    Investor Relations Contact:
    Kevin M. McGrath
    Cameron Associates, Inc.
    212 245 4577
    Kevin@cameronassoc.com

SOURCE Misonix, Inc.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule
2. Wyeth Applauds Six Countries Across Europe, and the Middle East, That Recently Announced the Inclusion of the 7-Valent Pneumococcal Conjugate Vaccine (PCV7) in Their Immunization Schedules
3. Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results
4. Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
5. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
6. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
7. PLC Systems Reports Fourth Quarter 2007 Results
8. Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
9. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
10. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2007 Financial Results
11. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... 3, 2016   Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that it is celebrating Hepatitis ... of two patients who tell their personal story and encourage those at risk to get ... Jacque: Hepatitis C ... ... Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.) ...
(Date:5/3/2016)... -- Forté Elements, LLC (Forté) is excited to announce the launch of its Mediceutical line ... of recovery for a variety of clinical conditions. Founded in 2013, Forté spent more ... Logo -  http://photos.prnewswire.com/prnh/20160502/362547LOGO ... ... ...
(Date:5/2/2016)... NEW YORK , May 2, 2016 /PRNewswire/ ... Series B financing of Graybug Vision, Inc. Graybug ... to developing therapies that may transform care for ... and glaucoma.  Graybug Vision,s technology was first developed ... out into a startup venture. ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... 04, 2016 , ... Nike Rugby Camp's success is due in large part ... of Elite Rugby Camps and current Nike Camp director, has offered an all abilities ... , “I’m excited for our eighth summer here in San Diego,” says Willis. "We ...
(Date:5/4/2016)... ... 2016 , ... All-Star Insurance of Northeast TX has announced ... their local community. The agency pledges to select a new beneficiary every 60 ... bring awareness to important local causes with fundraising and other support, by forming ...
(Date:5/4/2016)... ... May 04, 2016 , ... Dr. Elyson and Dr. Assili, ... at their office. Wisdom tooth removal, a common dental procedure, is performed for many ... are improperly erupted, resulting in risks of complications. By providing wisdom tooth removal surgery ...
(Date:5/4/2016)... ... , ... Francesca Loparco, Co-Founder of Queen City Dream Cars, an exotic car ... procedure at Christenbury Eye Center. The entrepreneur struggled with her computer, riding horses ... day as her in-office consultation and eye exam. Francesca’s eyesight was restored to 20/20 ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... small and compact tactical (6.7 inch) dual-light flashlights in models NSP-9842XL and ... NSP-9842XL (average retail starting at $59.95) uses 2 included CR-123 batteries to produce ...
Breaking Medicine News(10 mins):